SCHEMBL27711121

SCHEMBL27711121

CN1CCC(N(Cc2cccc(-c3ccc4[nH]ccc4c3)c2)C(=O)c2cnccn2)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 4/20 0.42
▸ CDK8 P49336 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ MAP3K11 Q16584 1/20 0.39
▸ CHRNB2 P17787 2/20 0.39
▸ CHRNB4 P30926 2/20 0.39
▸ CHRNA3 P32297 2/20 0.39
▸ CHRNA7 P36544 2/20 0.39
▸ CHRNA4 P43681 2/20 0.39
▸ GSK3B P49841 3/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ CSNK1D P48730 1/20 0.38
▸ MAPK11 Q15759 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ SLC6A9 P48067 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ SLC6A5 Q9Y345 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3692393 0.88 TP53 (0.43) DYRK1AMAP3K11MAP4K4CSNK1DMAPK11
SCHEMBL13604952 0.87 NPSR1 (0.43) DYRK1ANPSR1MAP3K11GSK3BCSNK1D
SCHEMBL27711112 0.87 NPSR1 (0.46) DYRK1ANPSR1MAP3K11GSK3BCSNK1D
SCHEMBL3698984 0.83 OPRM1 (0.48) —
SCHEMBL3693392 0.82 OPRM1 (0.43) CDK8
SCHEMBL13604748 0.82 OPRM1 (0.51) —
SCHEMBL13604953 0.78 KDM4E (0.48) DYRK1ANPSR1MAP3K11GSK3B
SCHEMBL3693110 0.77 DYRK1A (0.44) DYRK1AMAP3K11CHRNB2CHRNB4CHRNA3
SCHEMBL3695933 0.76 CACNA2D1 (0.38) CDK8
SCHEMBL6729935 0.76 FASN (0.40) DYRK1AMAP3K11CSNK1DMAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101242819-A Hypnotics and combinations of substituted biaryl and heteroaryl compounds and therapeutic uses thereof AVENTIS PHARMA INC (US) 2008-08-13 — — CN disclosed
Send feedback